

# Acting responsibly at Hikma

Being a responsible organisation and advancing our sustainability agenda is integral to how we do business.

Pursuing strong environmental, social and governance (ESG) programmes creates long-term value for both Hikma and our stakeholders and helps us deliver on our purpose to provide better health within reach, every day.

We are focused on the ESG issues that are most material to our business and stakeholders. These material issues form the basis of our sustainability framework and strategy and we align our business with these priorities.

- We advance health and wellbeing
- We empower our people
- We protect the environment
- We build trust through quality in everything we do

This section outlines how we address our most material ESG issues and highlights some of the major activities, milestones and achievements made throughout the year. More information on sustainability and ESG will be provided in our upcoming Sustainability Report 2023.

For more information visit  
[www.hikma.com/sustainability](http://www.hikma.com/sustainability)



## Focus on health at COP28

The Conference of the Parties (COP28) convention held in 2023 in Dubai, United Arab Emirates included a landmark recognition of the urgency for governments and organisations to address health impacts related to ongoing climate change. The declaration made on Health Day of the COP included a commitment to proactively address both the direct and indirect climate-related health impacts and was endorsed by 124 countries.

Climate change is currently among the most significant health threats globally. Climate change is expected to create both direct health impacts through heat waves,

droughts and other extreme weather events, as well as indirect health impacts such as increased prevalence of vector-borne and airways diseases, food and water insecurity, undernutrition, and forced displacements.

As a manufacturer of generic medicines, we recognise our role in mitigating the health-related impacts of global climate change. We do so by prioritising the availability and access of medicines, addressing and anticipating national health priorities and evolving patient needs, and working within our markets to launch more products and strengthen the resilience of healthcare systems.



We recognise our role in mitigating the health-related impacts of global climate change."